Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003450 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003450 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center.
The verdict
NCT00003450, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of gene therapy using the p53 gene in treating patients with advanced recurrent or persistent ovarian cancer or primary peritoneal cavity cancer.
Interventions
- BIOLOGICAL Ad5CMV-p53 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 1999-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003450
The ClinicalTrials.gov registry entry for NCT00003450 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad5CMV-p53 gene is the first listed.
NCT00003450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003450 about?
NCT00003450 is a clinical study titled "Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer". RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of gene therapy using the p53 gene in treating patients with advanced recurrent or persi...
What is the current status of trial NCT00003450?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-09. Estimated completion is 1999-01.
What interventions are being tested in trial NCT00003450?
The interventions under investigation include: Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003450?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.